Amending the definition of "psilocybin" in the uniform controlled substances act to exclude the pharmaceutical composition of crystalline polymorph psilocybin and adding crystalline polymorph psilocybin to schedule IV of the uniformed controlled substance act.

This bill redefines "psilocybin" in Kansas law to exclude pharmaceutical forms of crystalline polymorph psilocybin. It specifically adds this purified pharmaceutical form to Schedule IV of the controlled substances list, while keeping natural psilocybin (e.g., in mushrooms) subject to stricter controls. The change creates a legal pathway for pharmaceutical companies like Compass Pathways to develop and distribute psilocybin-based medications. This affects researchers, pharmaceutical manufacturers, and medical providers seeking to legally use this specific drug formulation.